James R McDonald, Andrew G Renehan, Sarah T O'Dwyer, Department of Surgery, The Christie NHS Foundation Trust, Manchester M20 4BX, United Kingdom.
World J Gastrointest Surg. 2012 Jan 27;4(1):9-19. doi: 10.4240/wjgs.v4.i1.9.
The prognostic significance of identifying lymph node (LN) metastases following surgical resection for colon and rectal cancer is well recognized and is reflected in accurate staging of the disease. An established body of evidence exists, demonstrating an association between a higher total LN count and improved survival, particularly for node negative colon cancer. In node positive disease, however, the lymph node ratios may represent a better prognostic indicator, although the impact of this on clinical treatment has yet to be universally established. By extension, strategies to increase surgical node harvest and/or laboratory methods to increase LN yield seem logical and might improve cancer staging. However, debate prevails as to whether or not these extrapolations are clinically relevant, particularly when very high LN counts are sought. Current guidelines recommend a minimum of 12 nodes harvested as the standard of care, yet the evidence for such is questionable as it is unclear whether an increasing the LN count results in improved survival. Findings from modern treatments, including down-staging in rectal cancer using pre-operative chemoradiotherapy, paradoxically suggest that lower LN count, or indeed complete absence of LNs, are associated with improved survival; implying that using a specific number of LNs harvested as a measure of surgical quality is not always appropriate. The pursuit of a sufficient LN harvest represents good clinical practice; however, recent evidence shows that the exhaustive searching for very high LN yields may be unnecessary and has little influence on modern approaches to treatment.
对于结肠癌和直肠癌患者,手术切除后识别淋巴结(LN)转移的预后意义已得到广泛认可,并反映在疾病的准确分期中。大量证据表明,总淋巴结计数较高与生存改善之间存在关联,尤其是对于淋巴结阴性的结肠癌。然而,在淋巴结阳性疾病中,淋巴结比率可能代表更好的预后指标,尽管这对临床治疗的影响尚未得到普遍确立。因此,增加手术淋巴结采集的策略和/或增加淋巴结产量的实验室方法似乎合乎逻辑,并可能改善癌症分期。然而,关于这些推断是否具有临床意义,存在争议,尤其是在寻求非常高的淋巴结计数时。目前的指南建议作为护理标准,至少采集 12 个淋巴结,但这种建议的证据值得怀疑,因为尚不清楚增加淋巴结计数是否会导致生存改善。现代治疗方法的发现,包括术前放化疗使直肠癌降期,反过来说明淋巴结计数较低,甚至完全没有淋巴结,与生存改善相关;这意味着使用采集的特定数量的淋巴结作为手术质量的衡量标准并不总是合适的。追求足够的淋巴结采集是良好的临床实践;然而,最近的证据表明,过度搜索非常高的淋巴结产量可能是不必要的,并且对现代治疗方法的影响很小。